MSD has received US Food and Drug Administration (FDA) approval for its anti-programmed death receptor-1 (PD-1) therapy, ...

Merck & Co.’s Keytruda has become the first immunotherapy approved by the FDA to be used around surgery to treat resectable ...

PFE's oncology portfolio, boosted by Seagen and late-stage pipeline assets, may fuel growth amid lackluster stock performance ...

Merck's Keytruda receives FDA approval for head and neck cancer after showing improved event-free survival in Phase 3 KEYNOTE-689 trial.

Alvotech and Dr. Reddy’s have entered into a collaboration and license agreement to co-develop, manufacture and commercialize ...

During a live event, Neal E. Ready, MD, and participants discussed use of PD-L1 status in non–small cell lung cancer and ...

SL Benfica, meanwhile, arrive in Orlando after a dramatic 2-2 draw with Boca Juniors. Their attacking quality is undeniable, ...

Currently, diagnosis of Parkinson’s and MSA is based on patients’ symptoms. Misdiagnosis often occurs, because the two ...

Pembrolizumab significantly reduced the risk of event free survival events by 30% compared with standard of care.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Keytruda marks the first perioperative anti-PD-1 treatment option for adults with PD-L1–positive resectable locally advanced ...

Keytruda was approved for locally advanced head and neck cancer before and after surgery, showing improved event-free ...